US Court of Appeals Reinstates Permanent Injunction
Against Abbott Laboratories for Infringing Innogenetics' Patent
"Innogenetics announced that
yesterday the U.S. Court of Appeals for the Federal Circuit made its first
substantive ruling in Abbott's appeal of a trial court's judgment and
injunction in favor of Innogenetics. The court denied Abbott Laboratories'
motion for a stay of injunction pending appeal."
Hospital Seeks Patients of Surgeon with Hepatitis C
[Canada] "Island health officials are contacting
hundreds of former patients of a general surgeon now that tests have
confirmed the doctor has hepatitis C. Dr. David Ashby is well with no
symptoms, Dr. Lamont Sweet, chief health officer for the Department of
Health, said yesterday."
Protein - Claudin-1- for Hepatitis C Virus Entry Identified
"For as many as 200 million people worldwide infected
with hepatitis C, a leading cause of chronic liver disease, treatment
options are only partially effective. But new research by Rockefeller
University scientists points to a potential new target for better
drugs: a key protein that resides in human liver cells that hepatitis C
requires for entry."
Idenix Announces Thirteen Data Presentations at the 2007
European Association For the Study of the Liver
"Idenix Pharmaceuticals, Inc., a biopharmaceutical company
engaged in the discovery, development and commercialization of drugs for
the treatment of human viral and other infectious diseases,
announced today that 13 abstracts have been accepted for presentation at
the 42nd annual meeting of the European Association for the Study of the
Liver (EASL), to be held in Barcelona, Spain, April 11-15, 2007."
Pharmasset Initiates Multiple Ascending Dose Study of
R7128 in Patients Chronically Infected with HCV Genotype 1
Pharmasset initiated the multiple ascending dose portion
of an on-going Phase 1 clinical trial evaluating R7128 in up to 40
patients chronically infected with hepatitis C virus (HCV) genotype 1.
"Pharmasset initiated the multiple ascending dose
portion of an on-going Phase 1 clinical trial evaluating R7128 in up to 40
patients chronically infected with hepatitis C virus (HCV) genotype 1. The
primary objective of this part of the study, being conducted in
collaboration with Roche, is to assess the safety, tolerability and
pharmacokinetics of multiple doses of R7128 after once-daily or
twice-daily dosing for 14 days."
New Culture System Leads to Anti-Viral Treatments for
"A new way of growing viruses in the laboratory
developed by Japanese researchers could spell hope for the 170 million
people infected with hepatitis C, only half of whom currently respond to
drug treatments, scientists announced today (Tuesday 27 March 2007) at the
Society for General Microbiology's 160th Meeting at the University of
Manchester, UK, which will run from 26 - 29 March 2007."
Human Genome Sciences Initiates Phase 3 Clinical Trial of
Albuferon With Ribavirin in Treatment-Naive Patients With Chronic
Hepatitis C Genotypes 2 and 3 - Enrollment of Both Phase 3 Trials of
Albuferon to be Completed in 2007
"Human Genome Sciences, Inc. today announced that it
has initiated dosing in ACHIEVE 2/3, a Phase 3 clinical trial of
Albuferon(R) (albinterferon alfa-2b) in combination with ribavirin in
treatment-naive patients with chronic hepatitis C genotypes 2 and 3.
ACHIEVE 2/3 is the second of two pivotal Phase 3 trials of Albuferon that
HGS is conducting, with the goal of filing global marketing applications
IND Filing for
Belerofon, Its Oral,
Long-Lasting, Interferon-alpha Drug
"Nautilus Biotech has announced that it has submitted
an Investigational New Drug (IND) filing to the US Food and Drug
Administration (FDA) for oral Belerofon(r), its long-lasting human
Interferon (IFN) alpha. Belerofon has therapeutic potential for the
treatment of a number of conditions, including chronic Hepatitis C. The
new drug will be administered orally - all currently marked interferon
alpha drugs are administered by injection - resulting in improved safety
and patient compliance."
Did State Fully Treat Inmate's Hepatitis?
"Alexis McCullough, an inmate at the Wichita Work
Release Center, died in excruciating pain, screaming for an ambulance,
last March. Afterward, I started raising questions: Why did no one call an
ambulance? Why was he allowed to suffer so? Now, there may be a bigger
question: Did the Kansas Department of Corrections contribute to his
condition by failing to sufficiently treat McCullough's chronic hepatitis
Better Infection Control Programs Needed to Help Combat
Hepatitis C in Egypt
"At least five million people in Egypt are infected
with the hepatitis C virus (HCV), a new committee formed by the country's
government to tackle the disease has said. It added that action must be
taken now to combat rising mortality."
Clinical Phase I Trial with Hepatitis C Virus Protease Inhibitor Initiated
"Medivir, on behalf of the Tibotec and Medivir
collaborative project, announced that this week Tibotec initiated a phase
I clinical trial with a potent and selective hepatitis C virus (HCV)
NS3/4A protease inhibitor, for the treatment of chronic hepatitis C virus
infection. The phase Ia clinical trial is designed to assess the safety,
tolerability, and pharmacokinetics in healthy volunteers. The study will
be conducted in Europe."
Michael Houghton, Co-Discoverer of Hepatitis C and Lasker
Award Winner, to Become Epiphany Biosciences' Chief Scientific Officer
"Epiphany Biosciences Inc. announced today the
appointment of virologist Michael Houghton, PhD, as Chief Scientific
Officer (CSO). Dr. Houghton joins Epiphany following a distinguished
24-year career at Chiron where he was most recently Vice President of HCV
and Virology Research. In 1989, Dr. Houghton and his Chiron colleagues
were the first to identify the hepatitis C virus (HCV) in collaboration
with the CDC."
Transgene Initiates A Phase I Trial of its Therapeutic
Vaccine Candidate TG4040 for Patients Chronically Infected With the
Hepatitis C Virus
"Transgene S.A. announces today that the first
patients have been enrolled in a Phase I trial of its therapeutic vaccine
candidate TG4040 (MVA-HCV) for patients chronically infected with the
Hepatitis C Virus (HCV). The trial is part of a development programme
supported by Lyonbiopole, one of France's six world-class competitiveness
Privately-Backed Inquiry into Contaminated Blood [UK]
"After two decades of calls for a public
investigation into the exposure of thousands of haemophilia patients to
HIV and hepatitis C infected blood, an independent inquiry has been set up
with funding from charities and private donors. Announcing the inquiry,
Lord Morris of Manchester, president of the Haemophilia Society, said
successive governments have resolutely resisted a public inquiry since
1988, preferring in-house inquiries at the Department of Health (DH) into
narrowly defined aspects of the disaster."
Anita Roddick Reveals She has Hepatitis C
"Dame Anita Roddick, the founder of the Body Shop,
revealed yesterday that she is carrying hepatitis C and has cirrhosis of
the liver, one of the condition's long-term effects. The 64-year-old
entrepreneur said she had contracted hepatitis C through a blood
transfusion while giving birth to her youngest daughter, Sam, in
McGuinty Government Invests In Nursing Support Program For
Hepatitis C Patients [Canada]
"The McGuinty government is helping people with
hepatitis C get the nursing care and support they need to complete their
treatment regimen and lead healthier and more active lives, Health and Long-Term Care Minister George Smitherman announced today.
"People with hepatitis C often find it difficult to stick to their
treatments because of the side effects they suffer," said Smitherman.
"We want to provide patients with the nursing care and support they
need to complete their treatment program and improve their chances of
beating this disease." The government is providing $2.3-million to
hire up to 20 nurses who will provide support to approximately 1,500
patients a year in Ontario and ensure they follow their hepatitis C
Mayo Clinic Tests New Drug to Prevent Hepatitis C
Recurrence after Liver Transplant
"The Mayo Clinic Transplant Center is studying
whether Hepatitis C Immune Globulin (Human), an investigational drug
candidate known as Civacir, prevents the recurrence of hepatitis C-related
liver disease in liver transplant patients. Mayo Clinic sites in Arizona,
Florida and Minnesota are looking for adults to participate in this study.
Eligible participants must have hepatitis C and need a liver transplant.
Individuals who have liver cancer may participate."
clinical trials, cohort studies, and pilot studies
Fibrosis progression in hepatitis C positive liver
recipients after sustained virologic response to antiviral combination
therapy (interferon-ribavirin therapy). Bahra
M, et al. Transplantation.
2007 Feb 15;83(3):351-3.
Final results of a double-blind, placebo-controlled trial
of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C
patients with advanced fibrosis or cirrhosis. Pockros
PJ, et al. Hepatology.
2007 Mar; 45(3):569-78.
Pilot study of pegylated interferon-alpha 2a in dialysis
patients with chronic hepatitis C virus infection.Chan
TM, et al. Nephrology
(Carlton). 2007 Feb;12(1):11-7.
Alcohol and hepatitis C mortality among males and females
in the United States: a life table analysis. Chen CM, et al. Alcohol
Clin Exp Res. 2007 Feb;31(2):285-92.
A randomized trial of paroxetine to prevent
interferon-alpha-induced depression in patients with hepatitis C. Morasco
BJ, et al. J
Affect Disord. 2007 Feb 8; [Epub ahead of print]
Interferon-alpha-induced depressive symptoms are related
to changes in the cytokinenetwork but not to cortisol. Wichers
MC, et al. J
Psychosom Res. 2007 Feb;62(2):207-14.
Effect of iron depletion on serummarkers of
oxidative stress and serum liver enzymes in chronic hepatitis C: results
of a pilot study. Alexander
Int. 2007 Mar;27(2):268-73.
i.v.-drug users with chronic hepatitis C can be
efficiently treated with daily high dose induction therapy using consensus
interferon: an open-label pilot study. Witthoeft
J Gastroenterol. 2007 Jan 28;13(4):579-84.
Characterization of B cell lymphoma in patients with
Sjogren's syndrome and hepatitis C virus infection Ramos-Casals
M, et al.
Treatment of chronic hepatitis C virus in African
Americans with genotypes 2 and 3. Shiffman
ML, et al. Am
J Gastroenterol. 2007 Feb 22; [Epub ahead of print]
Clinical spectrum and histopathologic features of chronic
hepatitis C infection in children. Mohan P, et al. J Pediatr. 2007
Sustained virological response to interferon-alpha is
associated with improved outcome in HCV-related cirrhosis: A retrospective
S, et al. Hepatology.
Hepatic oxidative DNA damage correlates with iron overload
in chronic hepatitis C patients. Fujita N, et al. Free Radic Biol Med.
2007 Feb 1;42(3):353-62. Epub 2006 Nov 6.
basic and applied science, pre-clinical studies
Genetic distance and heterogenecity between quasispecies
is a critical predictor to IFN response in Egyptian patients with HCV
genotype-4. Zekri AR, et al. Virol J. 2007 Feb 14;4:16.
The nonstructural 5A protein of hepatitis C virus genotype
1b does not contain an interferon sensitivity-determining region. Brillet
R, et al. J Infect Dis. 2007 Feb 1;195(3):432-41. Epub 2006 Dec 18.
Inhibition of hepatitis C virus replication and expression
by small interfering RNA targeting host cellular genes. Xue
Q, et al. Arch
Virol. 2007 Feb 3; [Epub ahead of print]
Induction of high-molecular-weight
(HMW) tumor necrosis factor(TNF) alpha by hepatitis C virus (HCV) non-structural protein 3
(NS3) in liver cells is AP-1 and NF-kappaB-dependent activation. Hassan
M, et al. Cell Signal. 2007 Feb;19(2):301-11. Epub 2006 Aug 17.
A new epitope peptide derived from hepatitis C
virus 1b possessing the capacity to induce cytotoxic T-lymphocytes in
HCV1b-infected patients with HLA-A11, -A31, and -A33. Matsueda
S, et al. Cancer
Immunol Immunother. 2007 Jan 31; [Epub ahead of print]
Thymic stromal lymphopoietin transgenic mice develop
cryoglobulinemia and hepatitis with similarities to human hepatitis C
liver disease. Kowalewska
J, et al. Am
J Pathol. 2007 Mar;170(3):981-9.
Interleukin-4 induces human hepatocyte apoptosis through a
Fas-independent pathway. Aoudjehane
L, et al. FASEB
J. 2007 Feb 5; [Epub ahead of print]
Vaccine-induced early control of hepatitis C virus
infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Rollier
CS, et al. Hepatology.
Liver-related mortality in
human-immunodeficiency-virus-infected patients between 1995 and 2003 in
the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study)*. Rosenthal
E, et al. J
Viral Hepat. 2007 Mar;14(3):183-8.
Effect of hepatitis C virus
(HCV) treatment in fibrosis
progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected
with human immunodeficiency virus (HIV): A paired liver biopsy study.
M, et al. J
Hepatol. 2007 Jan 26; [Epub ahead of print]
Health-related quality of life in HIV-1-infected patients on
five-years longitudinal analysis accounting for dropout in the
APROCO-COPILOTE cohort (ANRS CO-8). Protopopescu
C, et al. Qual
Life Res. 2007 Feb 1; [Epub ahead of print]
Changes in the distribution of hepatitis C virus
genotypes over time in Spain according to HIV serostatus: implications for
HCV therapy in HCV/HIV-coinfected patients. Ramos B, et al. J Infect.
2007 Feb;54(2):173-9. Epub 2006 Mar 29.
CD4+ T Cell-Dependent Reduction in Hepatitis C
Virus-Specific Humoral Immune Responses after HIV Infection. Netski
DM, et al. J
Infect Dis. 2007 Mar 15;195(6):857-63. Epub 2007 Feb 7.
Mitochondrial DNA depletion in HIV-infected patients with
chronic hepatitis C and effect of pegylated interferon plus ribavirin
Mendoza C, et al. AIDS.
2007 Mar 12;21(5):583-8.
Self-reported hepatitis B and C virus infections had low
sensitivity among HIV-infected patients. Lo
Re V 3rd, et al. J
Clin Epidemiol. 2007 Mar;60(3):294-9. Epub 2006 Nov 13.
Factors associated with reported hepatitis C and HIV among
injecting drug users in ten European cities. March
Infecc Microbiol Clin. 2007 Feb;25(2):91-97.
Factors associated with seronegative chronic hepatitis C
virus infection in HIV infection. Chamie G, etal. Clin Infect Dis.
2007 Feb 15;44(4):577-83.
The impact of cirrhosis on CD4+ T cell counts in
patients. McGovern BH, et al. Clin Infect Dis. 2007 Feb 1;44(3):431-7.
Epub 2006 Dec 21.
complimentary and alternative therapies
Viusid, a nutritional supplement, in combination with
interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Vilar
Gomez E, et al. Liver
Int. 2007 Mar;27(2):247-59
Results of a general hepatitis C lookback program for
persons who received blood transfusions in a neonatal intensive care unit
between January 1975 and July 1992. Cagle
HH, et al. Arch
Pediatr Adolesc Med. 2007 Feb;161(2):125-30.
Effectiveness of a multi-disciplinary standardized
management model in the treatment of chronic hepatitis C in drug addicts
engaged in detoxification programmes. Guadagnino
V, et al. Addiction.
The effects of HCV infection and management on
health-related quality of life. Younossi
Hepatitis C treatment candidacy and outcomes among 4318 US
veterans with chronic hepatitis C virus infection: does a history of
injection drug use matter? Seal KH, et al. J Clin Gastroenterol. 2007
A novel, sensitive, and specific RT-PCR technique for
quantitation of hepatitis C virus replication. Carriere M, et al. J
Med Virol. 2007 Feb;79(2):155-60.